Axonics Modulation Technologies Inc (AXNX)vsMerck & Company Inc (MRK)
AXNX
Axonics Modulation Technologies Inc
$0.43
-12.47%
HEALTHCARE · Cap: $3.63B
MRK
Merck & Company Inc
$148.30
+3.25%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15313% more annual revenue ($66.57B vs $431.90M). MRK leads profitability with a 4.8% profit margin vs -1.3%. MRK earns a higher WallStSmart Score of 36/100 (F).
AXNX
Hold36
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AXNX.
Margin of Safety
-72.1%
Fair Value
$83.44
Current Price
$148.30
$64.86 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 845.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.8% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Negative free cash flow — burning cash
Currently unprofitable
Operating margin of -2.4%
Trading at 8.7x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AXNX
The strongest argument for AXNX centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 24.8% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : AXNX
The primary concerns for AXNX are Free Cash Flow, Profit Margin, Operating Margin.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
AXNX profiles as a growth stock while MRK is a value play — different risk/reward profiles.
AXNX carries more volatility with a beta of 0.83 — expect wider price swings.
AXNX is growing revenue faster at 24.8% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
AXNX scores higher overall (36/100 vs 36/100) and 24.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Axonics Modulation Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
Axonics, Inc., a medical technology company, is dedicated to the development and commercialization of sacral neuromodulation (SNM) systems. The company is headquartered in Irvine, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?